Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
James Kirkland
Mayo Clinic Rochester, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cenexys, Inc. (nka Unity Biotechnology)
Other : Total IP royalties, through Mayo Clinic
Please see attached.
Role of senescent cells in the pathogenesis of Marfan-associated cardiovascular disease
PROJECT NARRATIVE Marfan syndrome affects 1 in every 5000 live births worldwide, with the multiple highly penetrant cardiac phenotypes (including mitral valve prolapse, aortic valve regurgitation, and aortic aneurysms) leading to multiple major cardiovascular surgeries throughout a patient's life. Currently, there are extremely limited treatment options to slow multi-organ degeneration in Marfan syndrome, with most treatments providing limited effectiveness in slowing disease. Critically, recent studies by our research group at Mayo (Miller/Kirkland) suggests that accumulation of senescent cells can drive progression of multiple diseases in pre-clinical models of chronological aging and human disease. Here we aim to show that senescent cells play a critical role in driving multiple cardiovascular diseases using genetically altered mice, pharmacological interventions in pre- clinical animal models of Marfan syndrome, and evaluation of senescent cell burden in human tissues. Collectively, we believe these studies will lay a foundation for innovative therapies that can slow progression of cardiovascular disease in patients with Marfan syndrome, and if successful, will accelerate the rate at which the field will move towards clinical trials in this arena.
Filed on May 15, 2019.
Tell us what you know about James Kirkland's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “James Kirkland”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology | $150,000 - $199,999 |
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $40,000 - $59,999 |
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $100,000 - $149,999 |
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $150,000 - $199,999 |
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $300,000 - $349,999 |
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $350,000 - $399,999 |
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $40,000 - $59,999 |
| James Kirkland | Mayo Clinic Rochester | Conflict of Interest | Cenexys, Inc. (nka Unity Biotechnology) | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.